Supraspinal μ2-opioid receptors mediate spinal/supraspinal morphine synergy

Chaim G. Pick; Bernard Roques; Gilles Gacel; Gavril W. Pasternak

doi:10.1016/0014-2999(92)90761-R

Supraspinal μ₂-opioid receptors mediate spinal/supraspinal morphine synergy

Chaim G. Pick, Bernard Roques, Gilles Gacel, Gavril W. Pasternak^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Abstract

TRIMU-5 (Tyr-D-Ala-Gly-NHC₂H₄CH(CH₃)₂) is a potent μ₂-opioid agonist/μ₁-opioid antagonist. A supraspinal dose (0.5 μg i.c.v.) of TRIMU-5 which is not analgesic when given alone antagonizes the analgesia produced by intracerebroventricular (i.c.v.) morphine, a μ₁ action. In contrast, in a synergy model consisting of the simultaneous administration of intrathecal morphine (0.1 μg) with multiple doses of i.c.v. morphine, the same supraspinal TRIMU-5 dose (0.5 μg i.c.v.) enhances analgesia. Supraspinal TRIMU-5 also potentiates spinal morphine directly, shifting its dose-response to the left. These results imply that within the brainstem μ₁ receptors mediate supraspinal analgesia while μ₂ receptors mediate the synergy with spinal μ systems.

Original language	English
Pages (from-to)	275-277
Number of pages	3
Journal	European Journal of Pharmacology
Volume	220
Issue number	2-3
DOIs	https://doi.org/10.1016/0014-2999(92)90761-R
State	Published - 22 Sep 1992
Externally published	Yes

Funding

Funders	Funder number
National Institute on Drug Abuse	R01DA007242

Keywords

Analgesia
Morphine
μ-Opioid receptors

Access to Document

10.1016/0014-2999(92)90761-R

Cite this

@article{e5169fd95736411ebe2e3a83d9bc27cf,

title = "Supraspinal μ2-opioid receptors mediate spinal/supraspinal morphine synergy",

abstract = "TRIMU-5 (Tyr-D-Ala-Gly-NHC2H4CH(CH3)2) is a potent μ2-opioid agonist/μ1-opioid antagonist. A supraspinal dose (0.5 μg i.c.v.) of TRIMU-5 which is not analgesic when given alone antagonizes the analgesia produced by intracerebroventricular (i.c.v.) morphine, a μ1 action. In contrast, in a synergy model consisting of the simultaneous administration of intrathecal morphine (0.1 μg) with multiple doses of i.c.v. morphine, the same supraspinal TRIMU-5 dose (0.5 μg i.c.v.) enhances analgesia. Supraspinal TRIMU-5 also potentiates spinal morphine directly, shifting its dose-response to the left. These results imply that within the brainstem μ1 receptors mediate supraspinal analgesia while μ2 receptors mediate the synergy with spinal μ systems.",

keywords = "Analgesia, Morphine, μ-Opioid receptors",

author = "Pick, {Chaim G.} and Bernard Roques and Gilles Gacel and Pasternak, {Gavril W.}",

year = "1992",

month = sep,

day = "22",

doi = "10.1016/0014-2999(92)90761-R",

language = "אנגלית",

volume = "220",

pages = "275--277",

journal = "European Journal of Pharmacology",

issn = "0014-2999",

publisher = "Elsevier B.V.",

number = "2-3",

}

TY - JOUR

T1 - Supraspinal μ2-opioid receptors mediate spinal/supraspinal morphine synergy

AU - Pick, Chaim G.

AU - Roques, Bernard

AU - Gacel, Gilles

AU - Pasternak, Gavril W.

PY - 1992/9/22

Y1 - 1992/9/22

N2 - TRIMU-5 (Tyr-D-Ala-Gly-NHC2H4CH(CH3)2) is a potent μ2-opioid agonist/μ1-opioid antagonist. A supraspinal dose (0.5 μg i.c.v.) of TRIMU-5 which is not analgesic when given alone antagonizes the analgesia produced by intracerebroventricular (i.c.v.) morphine, a μ1 action. In contrast, in a synergy model consisting of the simultaneous administration of intrathecal morphine (0.1 μg) with multiple doses of i.c.v. morphine, the same supraspinal TRIMU-5 dose (0.5 μg i.c.v.) enhances analgesia. Supraspinal TRIMU-5 also potentiates spinal morphine directly, shifting its dose-response to the left. These results imply that within the brainstem μ1 receptors mediate supraspinal analgesia while μ2 receptors mediate the synergy with spinal μ systems.

AB - TRIMU-5 (Tyr-D-Ala-Gly-NHC2H4CH(CH3)2) is a potent μ2-opioid agonist/μ1-opioid antagonist. A supraspinal dose (0.5 μg i.c.v.) of TRIMU-5 which is not analgesic when given alone antagonizes the analgesia produced by intracerebroventricular (i.c.v.) morphine, a μ1 action. In contrast, in a synergy model consisting of the simultaneous administration of intrathecal morphine (0.1 μg) with multiple doses of i.c.v. morphine, the same supraspinal TRIMU-5 dose (0.5 μg i.c.v.) enhances analgesia. Supraspinal TRIMU-5 also potentiates spinal morphine directly, shifting its dose-response to the left. These results imply that within the brainstem μ1 receptors mediate supraspinal analgesia while μ2 receptors mediate the synergy with spinal μ systems.

KW - Analgesia

KW - Morphine

KW - μ-Opioid receptors

UR - http://www.scopus.com/inward/record.url?scp=0026658495&partnerID=8YFLogxK

U2 - 10.1016/0014-2999(92)90761-R

DO - 10.1016/0014-2999(92)90761-R

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

AN - SCOPUS:0026658495

SN - 0014-2999

VL - 220

SP - 275

EP - 277

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

IS - 2-3

ER -